ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Vision-Focused Nomogram for Assessing the Risk of Depression in Diabetic Retinopathy: Integrating Visual Function, Metabolic Factors and Psychosocial Status.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate a comprehensive nomogram integrating visual function, metabolic factors, and psychosocial measures for assessing the risk of depression risk in patients with type 2 diabetic retinopathy (DR), using a robust machine learning-based feature selection approach. Methods: This cross-sectional study enrolled 490 DR patients from January 2020 to March 2025. Participants were randomly allocated to a training cohort (n=343) and an internal validation cohort (n=147). We assessed nineteen candidate variables. To identify the most significant and consistent predictors, a multi-step feature selection was employed: 1) LASSO regression with 10-fold cross-validation, 2) Stepwise Forward Logistic Regression, and 3) Random Forest importance ranking. The intersection of key variables from all three methods was used to build the final nomogram via multivariate logistic regression. Model performance was evaluated using ROC curves, calibration plots, 10-fold cross-validation, decision curve analysis, and SHAP for interpretability. Temporal validation was performed on an independent cohort (n=104) from the same center (June 2025-December 2025). Results: The overall prevalence of depressive symptoms was 29.18% (143/490). The integrative feature selection identified four robust independent predictors: glycated hemoglobin (HbA1c) (OR=1.716, 95% CI: 1.438-2.049), sleep quality index (PSQI score) (OR=1.306, 95% CI: 1.146-1.488), social support score (SSRS score) (OR=0.883, 95% CI: 0.824-0.947), and vision-related quality of life (VRQoL score) (OR=1.138, 95% CI: 1.094-1.183). The nomogram demonstrated excellent discrimination in the training cohort (AUC=0.918, 95% CI: 0.886-0.950) and internal validation cohort (AUC=0.867, 95% CI: 0.797-0.936), with good calibration. The 10-fold cross-validation yielded a stable average AUC of 0.891. SHAP analysis confirmed VRQoL as the most influential predictor. In temporal validation, the model maintained good performance (AUC=0.875, 95% CI: 0.805-0.946). Conclusion: This vision-focused nomogram, developed through a robust multi-method feature selection process, provides an effective and interpretable tool for depression risk stratification in DR patients. It integrates key clinical and patient-reported outcomes, demonstrating good and stable discriminative performance, and can assist clinicians in early screening of high-risk individuals for timely intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.